Showing results (231-240 of 454) with videos related to
Sort By:
Pageof 46
Journal of Viral Hepatitis|February 28, 2020
Unexpected long-lasting anti-HEV IgM positivity: Is HEV antigen a better serological marker for hepatitis E infection diagnosis?Mar Riveiro-Barciela, Ariadna Rando-Segura, Ana Barreira-Díaz, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 23, 2017
Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported OutcomesZobair M Younossi, Maria Stepanova, Tarik Asselah, et al.Intervirology|September 25, 2008
Genotyping of hepatitis B virus--genotypes a to g by multiplex polymerase chain reactionWen-Chun Liu, Magnus Lindh, Maria Buti, et al.Journal of Hepatology|November 1, 2011
Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort studyJorg Petersen, Vlad Ratziu, Maria Buti, et al.Liver International : Official Journal of the International Association for the Study of the Liver|April 25, 2020
Immune-related hepatitis related to checkpoint inhibitors: Clinical and prognostic factorsMar Riveiro-Barciela, Ana Barreira-Díaz, Judit Vidal-González, et al.Annals of Hepatology|February 21, 2014
Outcome of early vs. deferred antiviral treatment for recurrent hepatitis C in liver transplant recipientsIsabel Campos-Varela, Juan Ignacio Esteban, Marta Bes, et al.Journal of Hepatology|June 17, 2019
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAsJordi Llaneras, Mar Riveiro-Barciela, Sabela Lens, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 25, 2009
Predicting early mortality after acute variceal hemorrhage based on classification and regression tree analysisSalvador Augustin, Laura Muntaner, José T Altamirano, et al.Plos One|July 19, 2016
An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1)Tarik Asselah, Christophe Moreno, Christoph Sarrazin, et al.Alimentary Pharmacology & Therapeutics|August 6, 2026
Time to Positivity of a Rapid HBsAg Assay as a Surrogate Marker of Quantitative HBsAg: Multicentre Proof-of-Concept StudyAsegedech Asmamaw, Judit Romero, Nega Berhe, et al.Pageof 46